[CAS NO. 21062-28-2] SKOG102
PRODUCTS SPECIFICATIONS [21062-28-2]
DESCRIPTION [21062-28-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 422.35 |
| Molecular Formula | C19H25Cl2N7 |
| SMILES | N=C(NC1=NC(C)=CC(NC2CN(CC)CCC2)=N1)NC3=CC=C(Cl)C(Cl)=C3 |
Summary
SKOG102 is a potent OLIG2 inhibitor that is directly engaging OLIG2 and interferes with the ability of OLIG2 to bind DNA. SKOG102 can be used for the research of glioblastoma (GBM) [1] .
IC50 & Target
OLIG2 [1]
In Vitro
SKOG102 (0.1-5 μM; 72 h) inhibits human GBM4 and GBM8 cells grown as neurospheres, with IC
50
s of 10.66 and 1.536 μM, respectively
[1]
.
SKOG102 (0.5-5 μM; 12 h) increases p21 RNA levels and decreases OMG RNA levels in GBM4 cells
[1]
.
SKOG102 (5 μM; 20 h) suppresses OLIG2-DNA binding, and decreases the serine phosphorylated OLIG2 and total OLIG2 protein levels in GBM8 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SKOG102 (10-20 mg/kg; i.p.) inhibits GBM4 tumor growth in mice
[1]
.
SKOG102 (5 mg/kg; i.p.) accumulates in the tumor even over a relatively brief time period and the plasma and brain concentrations are almost identical at 4 hours after injection in mice
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | NSG mice were inoculated in each flank with GBM4 cells [1] |
| Dosage: | 10, 15, and 20 mg/kg; dissolved in solutol:PEG400:water (20%:40%:40%) |
| Administration: | Intraperitoneal injection; first 2 weeks (from day 33 to 46) 10 mg/kg, third week (from day 47 to 54) 15 mg/kg, fourth week (from 55 to 66) first 3 days 20 mg/kg, 2 days break, then alternate days from day 60 to 66 |
| Result: | Significantly attenuated tumor growth. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.